Lytix Biopharma

Be the first to follow this company

ShowingAll content types

Regulatory press release12/23/2024, 4:26 PM

Lytix Biopharma AS - New share capital registered

Lytix Biopharma

Regulatory press release12/17/2024, 7:05 AM

Lytix Biopharma AS: Key information relating to potential subsequent offering

Lytix Biopharma

Regulatory press release12/17/2024, 7:05 AM

Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates

Lytix Biopharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Regulatory press release12/16/2024, 11:30 PM

Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed

Lytix Biopharma

Regulatory press release12/16/2024, 4:09 PM

Lytix Biopharma AS: Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement

Lytix Biopharma

Regulatory press release12/16/2024, 4:04 PM

Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid

Lytix Biopharma

Regulatory press release12/16/2024, 3:45 PM

Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement

Lytix Biopharma

Regulatory press release11/21/2024, 2:48 PM

Lytix Biopharma AS: Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion

Lytix Biopharma

Press release11/20/2024, 9:35 AM

Redeye: Lytix Q3 2024 - First Patient in NeoLIPA

Lytix Biopharma

Regulatory press release11/19/2024, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

Lytix Biopharma

Regulatory press release11/12/2024, 9:33 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q3 2024 Results Presentation

Lytix Biopharma

Press release11/6/2024, 9:23 PM

Lytix Biopharma AS: First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma

Lytix Biopharma

Regulatory press release11/6/2024, 12:34 PM

First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma

Lytix Biopharma

Regulatory press release11/5/2024, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Lytix Biopharma

Regulatory press release11/5/2024, 6:00 AM

Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals

Lytix Biopharma

Regulatory press release11/1/2024, 6:04 AM

LYTIX: Financial calendar

Lytix Biopharma

Regulatory press release10/24/2024, 12:19 PM

Lytix Biopharma AS: Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference

Lytix Biopharma

Press release8/29/2024, 11:31 AM

Redeye: Lytix Q2 2024 - Verrica’s Phase II Data Changes the Case

Lytix Biopharma

Regulatory press release8/29/2024, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization

Lytix Biopharma

Regulatory press release8/23/2024, 6:05 AM

Lytix Biopharma AS: Lytix Biopharma: Invitation to Q2 2024 Results Presentation

Lytix Biopharma

Lytix Biopharma

Join Inderes community

Inderes account

Stay up to date with our newsletter